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Abstract  99 
 100 
Background: Strict criteria for recombinant tissue plasminogen activator (rtPA) eligibility are 101 
stipulated on licences for use in ischaemic stroke, however, practitioners may also add non-standard 102 
rtPA criteria. We examined eligibility criteria variation in 3 English-speaking countries including use 103 
of non-standard criteria, in relation to rtPA treatment rates. 104 
  105 
Methods:  Surveys were mailed to 566 eligible hospitals in Australia (AUS), United Kingdom (UK) and 106 
the United States (USA). Criteria were pre-classified as standard (approved indication and 107 
contraindications licence) or non-standard (approved licence warning or researcher ‘decoy’). 108 
Percentage for criterion selection was calculated/compared; linear regression was used to assess the 109 
association between use of non-standard criteria and rtPA treatment rates, and to identify factors 110 
associated with addition of non-standard criteria.  111 
 112 
Results:  Response rates were 74% AUS, 65% UK, and 68% USA; mean rtPA treatment rates were 113 
8.7% AUS, 12.7% UK and 8.7% USA. Median percentage of non-standard inclusions was 33% (all 3 114 
countries) and included National Institutes of Health Stroke Scale (NIHSS) scores >4, computed 115 
tomography (CT) angiography documented occlusion, and favourable CT perfusion. Median 116 
percentage of non-standard exclusions was 25% AUS, 28% UK, and 60% USA, and included 117 
depressed consciousness, NIHSS>25, and use of antihypertensive infusions. No AUS or UK sites 118 
selected 100% of standard exclusions.  119 
 120 
Conclusions: Non-standard criteria for rtPA eligibility was evident in all three countries and could, in 121 
part, explain comparably low use of rtPA. Differences in the use of standard criteria may signify 122 
practitioner intolerance for those derived from original efficacy studies that are no longer relevant. 123 
 124 
  125 
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Introduction  126 
Intravenous thrombolysis with recombinant tissue plasminogen activator (rtPA) has been shown to 127 
be safe and effective, and is one of the few evidence based treatments for acute ischaemic stroke.[1-128 
5] Currently, the percentage of patients with ischaemic stroke receiving rtPA varies globally, with 7% 129 
to 9% treated in the stroke centre certified United States of America (USA) hospitals,[6] 7% in 130 
Australia (AUS)[7] and 13% treated in some European centres.[8]  The narrow time frame for 131 
therapeutic administration, which in the United Kingdom (UK) and AUS is within 4.5 hours of 132 
symptom onset and in the USA is within 3 (approved indication licence) or 4.5 (guidelines) hours, is 133 
one main factor for low treatment rates. However, improved rtPA treatment rates are possible when 134 
internal hospital organisational factors are addressed,[9-12] and when regional stroke systems are 135 
operationalised to support patients with acute stroke.[13-16] 136 
 137 
Eligibility criteria for rtPA are largely derived from clinical trials with the aim of producing similar 138 
beneficial outcomes in routine practice. However, the addition of local or “site-specific” (non-139 
standard) eligibility criteria may result in otherwise eligible patients not receiving rtPA. There is a 140 
growing evidence base on the additional reasons for low rtPA treatment rates, including the fit 141 
between eligibility criteria and actual patient selection practices.[17-19] In particular, many of the 142 
criteria used in clinical trials may no longer be relevant given that the drug was first approved over 143 
20 years ago.[20-22] Mounting evidence from pooled analyses, observational studies and clinical 144 
trials, some studying an extended time window of 4.56 hours and practices less adherent with 145 
standard criteria, suggests that rtPA can be delivered safely to patients previously deemed 146 
ineligible.[22-3128] 147 
 148 
The eligibility criteria for rtPA administration varies between countries.[3229-352] The European and 149 
Australian guidelines share many similarities, but these differ substantially from the USA guidelines, 150 
and the USA guidelines vary significantly from the drug’s approved indications and contraindications 151 
licence. Varying criteria between national drug regulatory bodies, professional organisations, and 152 
individual hospital protocols challenges international consensus on what constitutes patient 153 
eligibility for treatment. There is an urgent need to understand these issues, including the addition 154 
of non-standard criteria for selecting patients eligible for rtPA treatment. The aims of this study were 155 
to: 1) describe the criteria for patient selection for rtPA treatment by country; 2) to determine the 156 
association between the use of non-standard criteria and rtPA treatment rates in three different 157 
countries; and, 3) to identify the organisational factors associated with the addition of non-standard 158 
criteria. 159 
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 160 
 161 
Methods 162 
Ethics approval was obtained from the following institutions for the conduct of this study:  Eden 163 
Hospital, Castro Valley California (USA coordinating centre), the University of Central Lancashire (UK 164 
coordinating centre), and the Australian Catholic University (Australian, and overall international 165 
coordinating centre). We undertook a cross-sectional survey of rtPA eligibility and treatment 166 
practices within hospitals in Australia, the UK and the USA that routinely used rtPA for management 167 
of acute stroke patients.   The survey was conducted between 2013-2016 and analysed in 168 
2017. 169 
 170 
Hospital selection 171 
All hospitals in AUS and in the UK known to provide rtPA for acute ischaemic stroke were eligible for 172 
the study and were identified via the Stroke Foundation Organisational Survey[36]33 and The 173 
Sentinel Stroke National Audit Programme (SSNAP), respectively. In the USA, stroke centre hospitals 174 
were included based on the following inclusion criteria: 1) nationally certified by The Joint 175 
Commission for a minimum of 12 months at the time of survey mailing; 2) use of an organised acute 176 
stroke team in the approach to emergency diagnosis and treatment; and, 3) formal identification by 177 
policy and procedure of eligibility criteria for rtPA treatment.  178 
 179 
Survey distribution  180 
Within each hospital, one eligible staff member was identified to complete the survey: the Stroke 181 
Unit Co-ordinator in AUS and the USA and the SSNAP lead contact for the Trust in the UK Identified 182 
staff who were approached by mail (AUS and USA) or email (UK) with a letter inviting them to 183 
participate in the survey along with a copy of the questionnaire. Prior to this invitation, an advanced 184 
letter was sent to notify potential participants of the pending survey as a response aiding 185 
strategy.[37]34 Participation was voluntary and consent was implied by completion and return of 186 
the questionnaire. Completed questionnaires were returned via post, fax or completed and returned 187 
electronically. Non-respondents were followed-up by email or phone at six weeks and eight weeks in 188 
AUS and the UK. In the USA follow-up consisted of a second and third mail out at eight and 16 weeks 189 
from the initial mail out date.  190 
 191 
Survey content and development 192 
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The survey was originally designed for study in the USA and included both standard criteria for rtPA 193 
use in stroke patients (criteria stipulated by the USA rtPA approved indications and contraindications 194 
licence and/or guidelines) and non-standard criteria (i.e. decoys derived from interviews with both 195 
expert users and community neurologists in the USA). This survey was then tailored for use in AUS 196 
and UK by adding criteria specified by the relevant country: i) manufacturer, ii) drug regulatory body, 197 
and iii) stroke clinical guidelines (referred collectively as ‘practice recommendations’ hereafter). The 198 
Australian and UK version of the survey was pre-tested with a panel of experts (Neurologists, Stroke 199 
Clinicians and Stroke Nurses) to identify any ambiguous questions and to recommend further decoy 200 
criteria. All three versions of the surveys consisted of two main sections; one section listed all the 201 
inclusion criteria, and one section listed all the exclusion criteria. Participants were instructed to 202 
select all of the criteria that were used at their hospital to assess if patients are eligible for rtPA.  203 
Additional space was provided for participants to write in criteria that were not included on the 204 
questionnaire. Information was also collected on organisational factors which included type of 205 
stroke service (tertiary / non-tertiary referral centre), number of beds, number of ischaemic stroke 206 
admissions in the last 12 months, rtPA treatments in the last 12 months, door-to-needle time and 207 
who was involved in the selection and decision-making process for rtPA. 208 
 209 
Data Analysis  210 
Descriptive analyses were used to summarise the self-reported characteristics of the stroke services 211 
by country. Criteria for patient selection for rtPA were pre-classified as either “standard” (an 212 
inclusion or exclusion specified by country practice recommendations) or “non-standard” (warnings 213 
specified by country practice recommendations or decoy criteria developed by the researchers).  To 214 
determine criteria being used, the percentage of respondents that selected each criterion was 215 
calculated. For each hospital, the proportion of standard and nonstandard criteria of the total 216 
criteria was calculated. The proportion calculated for each hospital was summarised for each 217 
country and reported as a median percentage. Criteria added by respondents were independently 218 
reviewed by study investigators (LC, HH, AA), and classified to existing groups if meanings were 219 
similar or classified as non-standard criteria if meanings were unique. Treatment rates were 220 
calculated for each hospital using the number of annual rtPA treatments reported, divided by the 221 
number of annual ischemic stroke admissions, multiplied by 100.  Independent Student t-tests and 222 
one-way analysis of variance (ANOVA) were undertaken to examine the associations between pre-223 
specified stroke service variables (hospital setting [tertiary/non-tertiary] and door to needle times) 224 
and rtPA treatment rates in each country.  Linear regression analyses were conducted for each of 225 
the countries to assess associations between non-standard criteria and rtPA treatment rates. Linear 226 
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regression models were developed using preselected variables to identify organisational factors 227 
associated with the addition of non-standard criteria in each country. Analyses were conducted with 228 
Stata version 14. 229 
 230 
Results 231 
The response rates per country were 68% (AUS 74% (63/85), UK 65% (93/144) and USA 68% 232 
(229/337).  Tertiary hospital staff made up 39% of respondents overall (AUS 46%; UK 53%; USA 29%), 233 
with 38% of AUS respondents and 69% of USA respondents reporting comprehensive stroke centre 234 
(CSC) capabilities (CSC status was not reported on the UK survey) (Supplement Table A). Decision 235 
makers for treatment with rtPA in AUS and the USA were most commonly neurologists (84% and 236 
87%, respectively), whilst the majority of UK respondents selected stroke (usually geriatrician) 237 
physicians (99%).  Interestingly, 31% of USA centres would only accept an rtPA order from a 238 
neurologist.  Telemedicine was not used in 68% and 39% of AUS and UK respondents respectively 239 
(not collected on USA survey) (Supplement Table A).  240 
 241 
Differences in rtPA Treatment Rates 242 
Of responding stroke centres, 60 (95%) AUS, 77 (83%) UK, and 184 (80%) USA centres included both 243 
their annual ischaemic stroke patient volumes and their annual rtPA treatment volumes enabling 244 
calculation of rtPA treatment rates.  Mean rtPA treatment rate for Australia, UK and USA were 8.7% 245 
(SD=5.8), 12.7% (SD=4.7) and 8.7% (SD=6.4), respectively. Supplement Table B shows differences in 246 
rtPA treatment rates by tertiary care designation and door-to-needle times. Rates for rtPA 247 
treatments were consistently higher for tertiary than non-tertiary hospitals and increased with 248 
shorter door-to-needle time for all three countries, although differences in mean rates were only 249 
significantly different for USA (F 7.64; p<0.001).  250 
Selection of Inclusion Criteria for rtPA Treatment 251 
The median percentage of standard criteria selected by USA (50%; IQR 25) respondents was less 252 
than that selected by AUS (100%; IQR 33) and UK (100%; IQR 0) respondents. The median 253 
percentage of non-standard criteria selected by respondents from all three countries was 33%. 254 
 255 
Table 1 lists standard and non-standard inclusion and exclusion criteria and their rates of selection 256 
by country. The standard USA approved licence inclusion criterion, ‘Ability to start rtPA within 3 257 
hours from symptom onset’ was selected by almost a quarter of USA respondents.  The non-standard 258 
criterion for limiting inclusion to patients with National Institutes of Health Stroke Scale scores 259 
greater than 4 points was selected by about half of respondents from AUS (49%) and the UK (51%), 260 
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and 35% of USA respondents.  The non-standard criterion for a favourable computed tomographic 261 
(CT) perfusion (CTP) scan in patients inside the window for rtPA treatment was selected by 22% of 262 
AUS and 19% of USA respondents, whereas only 11% of UK respondents selected this criterion.  263 
Additionally, 21% and 26% of AUS and USA respondents respectively required evidence of occlusion 264 
on CT angiography (CTA) as an rtPA non-standard inclusion criterion, compared to 16% of UK 265 
respondents.   266 
  267 
Selection of Exclusion Criteria for rtPA Treatment 268 
The median percentage of standard exclusion criteria selected by USA (82%; IQR 18) respondents 269 
was higher than that selected by AUS (66%; IQR 24) and UK (64%; IQR 25) respondents. The median 270 
percentage of non-standard exclusions selected by USA respondents (60%; IQR 60) was again higher 271 
than that selected by AUS (25%; IQR 19) and UK (28%; IQR 17) respondents.  272 
 273 
There were no respondents within AUS or the UK that selected all their country’s standard exclusion 274 
criteria, and all AUS and UK respondents added non-standard exclusion criteria.  Both “NIHSS > 25” 275 
and “altered level of consciousness (obtunded, stuporous, or comatose)” were selected by 62% and 276 
42% of AUS and UK respondents respectively, whereas 31% of USA respondents reported that their 277 
hospital excluded patients with NIHSS > 25, and 7% of USA respondents’ hospitals excluded patients 278 
with altered level of consciousness.  Additionally, 29%, 24% and 7% of AUS, UK and USA respondents 279 
indicated that their hospital excludes patients from rtPA treatment if they require a continuous IV 280 
infusion of an antihypertensive agent.  Patients with large vessel occlusion (LVO) were considered an 281 
exclusion for rtPA treatment by 14% of USA respondents, in favour of endovascular management, 282 
whereas 1.6% and 8.6% of AUS and UK respondents respectively reported that their hospitals 283 
exclude LVO from rtPA treatment in favour of endovascular treatment.  Age greater than 80 years 284 
was listed as an exclusion by 13% and 16% of AUS and USA respondents respectively, compared to 285 
only 3% of UK respondents, regardless of whether treating within the 3 or 4.5-hour treatment 286 
window. 287 
 288 
Relationship of Non-Standard Criteria to rtPA Treatment 289 
As the number of non-standard inclusions and exclusions increased, rtPA treatment rates slightly 290 
decreased in all three countries. As the number of non-standard criteria increased by one the rtPA 291 
rate decreased by 0.48% (p=0.05), 0.31% (p=0.07) and 0.16% (p=0.13) for AUS, UK and the USA, 292 
respectively. 293 
 294 
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Association Between Factors and the Addition of Non-Standard Criteria 295 
Factors significantly associated with the addition of non-standard criteria in the USA were as follows: 296 
non-tertiary hospital setting (-1.72 [95%CI -3.25, -0.20]); p-value=0.03); average door-to-needle time 297 
greater than 60 minutes (3.57 [95%CI -0.38, 6.75]; p-value=0.023) and adherence to 3-hour 298 
treatment window (-2.44 [95%CI -4.30, -0.60]); p-value=0.01). No factors were significantly 299 
associated with the addition of non-standard criteria in AUS or in the UK (Supplement Table C). 300 
 301 
Discussion 302 
Our study found that clinicians commonly develop and use non-standard criteria for selection of rtPA 303 
eligible patients. Importantly, both AUS and the UK have greater numbers of standard criteria 304 
compared to the USA, yet participants from these countries use more non-standard criteria than in 305 
the USA. The use of non-standard exclusion criteria has been investigated in other studies, however, 306 
the aims of most of these studies were to identify the impact of non-standard eligibility criteria on 307 
early clinical outcomes such as rates of symptomatic intracerebral haemorrhage (sICH).[20-23,3835]   308 
To the best of our knowledge, our study appears to be the only one examining clinicians’ formal 309 
protocol additions of non-standard criteria in relation to rtPA treatment rates.  310 
 311 
There were a number of differences in the criteria between countries relating to the use of both 312 
standard and non-standard exclusion criteria. Differences in use of standard criteria between 313 
countries could signify clinical uncertainty, conflicting research evidence, or perhaps an intolerance 314 
for continued use of criteria that supported efficacy studies of rtPA in acute ischemic stroke but may 315 
not be relevant outside a phase III clinical trial.  For example, both severe neurologic disability and 316 
blood glucose limits were considered warnings but not contraindications on the former (prior to 317 
February 2015) [396] USA label for rtPA, whereas the Australian and UK labels continue to stipulate 318 
specific limits from which to exclude rtPA treatment. Interestingly, the February 2015 USA Food and 319 
Drug Administration (FDA) rtPA approved label [396] removed severe neurologic disability as a 320 
precaution, based on findings from the original National Institute of Neurological Disorders and 321 
Stroke rtPA Stroke Study that showed significant improvement in severe disability patients treated 322 
with rtPA compared to placebo.[4037]  Similarly, the 2015 USA FDA approved label [396] no longer 323 
cites blood glucose values as warnings, as these are easily monitored and managed in both the pre-324 
hospital and emergency department settings.  325 
 326 
The use of some standard exclusions was fewer than expected in both AUS and the UK. For example, 327 
less than 25% of participants in these countries selected the standard exclusion, patients with any 328 
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history of prior stroke and concomitant diabetes. Although the use of rtPA has not been approved in 329 
Europe for these patients, registry studies have shown that while this criterion may have been 330 
important in the ECASS-3 efficacy study,[2] it may not be relevant to real-world practice and does 331 
not jeopardise the safe treatment of patients with rtPA.[4138-4239] While trial methods do provide 332 
a degree of certainty about what results to expect in a similar population, use of approved therapies 333 
in the real world often calls for less exclusivity.[430]  334 
 335 
It has been recognised internationally that selection criteria may be too restrictive and some have 336 
expressed concerns that the evidence underpinning the need to include certain criteria is not 337 
robust.[20-28,430-452]  The 2015 USA FDA labeling requirements for prescription drugs, commonly 338 
referred to as the ‘Physician Labelling Rule’ (PLR), state ‘No implied claims or suggestions of drug use 339 
may be made if there is inadequate evidence of safety or a lack of substantial evidence of 340 
effectiveness,[463] meaning that unless there is high level evidence to support a safety concern, it 341 
should not be considered a contraindication. The USA FDA’s PLR requirements significantly reduced 342 
the number of USA exclusion criteria to seven in 2015, with previous stroke, seizure at onset, and 343 
history of intracranial haemorrhage removed; additionally, blood pressure cut off levels, as well as 344 
lab values for bleeding diathesis were also removed in favour of relying on evidence-based 345 
guidelines to set these values.[396]  The 2015 USA FDA label also removed precautions for severe 346 
neurologic deficit, major early infarct signs, minor neurologic deficit, and rapidly improving 347 
symptoms.[396[  Interestingly, the majority of the USA criteria that were removed, currently remain 348 
on the European and Australian labels, and we believe that this calls for a more thorough evaluation 349 
of whether these criteria are truly valid perhaps using the processes established by The Re-350 
examining Acute Eligibility for Thrombolysis (TREAT) Task Force is comprised members of the original 351 
NINDS rtPA Stroke Trial Steering Committee,[474] especially with sICH rates from more recent 352 
studies and registries commonly at less than 3%.[2,485-5249] The investigators of a recent study 353 
which aimed to assess whether adherence to drug labels is associated with efficacious patient 354 
outcomes concluded that product labels need to be revised, finding that adherence with product 355 
labels is highest with less efficacious interventions.[530] 356 
 357 
Limitations 358 
This study carries the limitations of survey research such as the risk of response and recall bias. First, 359 
we assume that findings submitted are truthful and accurately reflect the practice at the 360 
participating stroke centres, although this may not be the case. We also acknowledge that some 361 
items such as aortic arch dissection were not listed as criteria in the questionnaire for participants to 362 
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select. Additionally, surveys do not provide the meaning or context behind a response. Therefore, 363 
we are limited in our ability to provide an understanding of why and how clinicians make certain 364 
decisions including their areas of clinical or research uncertainty.[541] Lastly, although this 365 
questionnaire was personally addressed to Stroke Unit Coordinators, a variety of professional groups 366 
responded; while this was anticipated and encouraged by our instructions to ‘collaborate with 367 
colleagues, who are involved in the decision-making and administration of rtPA for stroke patients,’ it 368 
does potentially introduce a source of differential error and measurement error. Furthermore, this is 369 
a highly dynamic field, with new imagining criteria re-defining reperfusion strategies at different 370 
time points.[552,563] Therefore, it would be worthwhile to repeat this study as the reperfusion 371 
paradigm shifts. 372 
 373 
Strengths 374 
This research provides novel data about rtPA international administration practices and the 375 
differences in the use of selection criteria in three different countries, two with similar healthcare 376 
systems (AUS/UK), and the USA with a largely private health system. The survey had a reasonable 377 
response rate for all three countries which adds external validity to the findings, and our survey tools 378 
were extensively pre-tested with experts contributing face validity to our methods.  379 
 380 
Conclusion  381 
This study provides novel, and somewhat provocative data about the criteria used to select patients 382 
for rtPA across three English-speaking countries, in particular, the relatively common use of non-383 
standard criteria for rtPA eligibility which may contribute in part, to low rtPA treatment rates.  384 
  385 
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